Bisphosphonate-related osteonecrosis of the jaw: An overview

Annals of the New York Academy of Sciences

Volumn 1218, Issue 1, 2011, Pages 38-46

  Ruggiero, Salvatore L ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; BRONJ; ONJ; Osteonecrosis

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE CANCER; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; GENERAL PRACTITIONER; HUMAN; JAW OSTEONECROSIS; METASTASIS; MORBIDITY; NEOPLASM; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT MONITORING; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY OF LIFE; RISK FACTOR;

EID: 79551517591     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05768.x     Document Type: Article

References (69)

1. Coleman, R. & R. Rubens 1987. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55: 61-66.
2. Deftos, L. 2005. Treatment of Paget's disease-taming the wild osteoclast. N. Engl. J. Med. 353: 872-875.
3. Clain, A. 1985. Secondary malignant disease of bone. Br. J. Cancer. 19: 15-29.
4. Kanis, J. 1995. Bone and cancer: pathophysiology and treatment of metastases. Bone 17: 101S-105S.
5. Mundy, G. 1987. Bone resorption and turnover in health and disease. Bone 8: 9S-18S.
6. Glass, D., M. Patel & G. Karsenty 2003. A new insight into the formation of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349: 2479-2480.
7. Lerner, U. 2006. Bone remodeling in post-menopausal osteoporosis. J. Dent. Res. 85: 584-595.
8. Berensen, J., A. Lichtenstein & L. Porter 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334: 484-493.
9. Berensen, J., A. Lichtenstein & L. Porter 1998. Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. 16: 593-597.
10. Conte, P. & R. Coleman 2004. Bisphosphonates in the treatment of skeletal metastases. Semin. Oncol. 31: 59-63.
11. Hortobagyi, G., R. Theriualt & A. Lipton 1998. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16: 2038-2043.
12. Hortobagyi, G. et al 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N. Engl. J. Med. 335: 1785-1792.
13. Michaelson, M. & M. Smith 2005. Bisphosphonates for the treatment and prevention of bone metastases. J. Clin. Oncol. 23: 8219-8224.
14. van Holten-Verzantvoort, A., H. Kroon & O. Bijvoet 1993. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol. 11: 491-498.
15. Berenson, J. et al 2002. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 20: 3719-3736.
16. Hillner, B., J. Ingle & J. Berenson 2000. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J. Clin. Oncol. 18: 1378-1391.
17. United States Food and Drug Administration Oncologic Drugs Advisory Committee. 2005. Combidex briefing information.
18. Chestnut, C., S. Majumdar & J. Gardner 2001. Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites. Adv. Exp. Med. Biol. 496: 95-97.
19. Guyatt, G., A. Cranney & L. Griffith 2002. Summary of meta-analysis of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol. Metab. Clin. North Am. 31: 112-124.
20. Bilezikian, J. 2006. Osteonecrosis of the jaw-do bisphosphonates pose a risk? N. Engl. J. Med. 355: 2278-2281.
21. Gibbs, S., J. O'Grady & J. Seymour 2005. Bisphosphonate-induced osteonecrosis of the jaws requires early detection and intervention. Med. J. Austr. 183: 549-550.
22. Greenberg, M. 2004. Intravenous bisphosphonates and osteonecrosis (editorial). Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endond. 93: 259-260.
23. Marx, R., Y. Sawatari & M. Fortin 2005. Bisphosphonate-induced exposed bone (Osteonecrosis/Osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J. Oral Maxillofac. Surg. 63: 1567-1575.
24. Mehrotra, B. et al 2003. Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. A case report (abstract 3194). Proc. Am. Soc. Clin. Oncol. 22: 795-796.
25. Mehrotra, B. & S. Ruggiero 2005. Bisphosphonate related osteonecrosis (BRON) of the jaw: single institutional update. (abstract) Blood 106: 291-295.
26. Melo, M. & G. Obeid 2005. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. J. Am. Dent. Assoc. 136: 1675-1681.
27. Migliorati, C., M. Schubert & D. Petersen 2005. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer 104: 83-93.
28. Purcell, P. & I. Boyd 2005. Bisphosphonates and osteonecrosis of the jaw. Med. J. Austr. 182: 417-418.
29. Rosenberg, T. & S. Ruggiero 2003. Osteonecrosis of the jaws associated with the use of bisphosphonates. J. Oral Maxillofac. Surg. 61: 225.
30. Ruggiero, S., J. Fantasia & E. Carlson 2006. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endond. 102: 433-441.
31. Ruggiero, S., B. Mehrotra & T. Rosenberg 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62: 527-534.
32. Van Poznak, C. & B. Ward 2006. Osteonecrosis of the jaw. Curr. Opin. Orthop. 17: 1-7.
33. Vannucchi, A., G. Ficarra & E. Antonioli 2005. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br. Hematol. 128: 738-740.
34. Allen, M. & D. Burr 2008. Mandible matrix necrosis in beagle dogs following 3 years of daily oral bisphosphonate treatment. J. Oral. Maxillofac. Surg. 66: 987-994.
35. Stopeck, A., J. Body & Y. Fujiwara 2009. Denosumab versus zolendronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur. J. Cancer Suppl. 7: 2.
36. Aghaloo, T., A. Felsenfeld & S. Tetradis 2010. Osteonecrosis of the jaw in a patient on Denosumab. J. Oral Maxillofac. Surg. 68: 959-963.
37. Santini, D., B. Vincenzi & G. Avvisati 2002. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 8: 1080-1084.
38. Wood, J., K. Bonjean & S. Ruetz 2002. Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J. Pharm. Exp. Ther. 302: 1055-1061.
39. Landesberg, R. et al 2008. inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral Maxillofac. Surg. 66: 839-847.
40. Sarasquete, M. 2008. BRONJ is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide analysis. Blood 111: 2709.
41. Badros, A., D. Weikel & A. Salama 2006. Ostonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J. Clin. Oncol. 24: 945-952.
42. Cafro, A., L. Barbarano & A. Andriani 2005. Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: an Italian experience. (abstract) Blood. 106: 5152.
43. Dimopoulos, M., E. Kastritis & L. Moulopoulos 2005. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. (abstract) Blood. 106: 637.
44. Durie, B., M. Katz & J. Crowley 2005. Osteonecrosis of the jaw and bisphosphonates. (Letter). N. Engl. J. Med. 353: 99.
45. Gallucci, C., A. Agrillo & G. Iannetti 2005. Possible role of ozone therapy in the treatment of osteonecrosis of the jaw in multiple myeloma patients. (abstract). Blood 106: 3460.
46. Migliorati, C., J. Casiglia & J. Epstein 2005. Managing the care of patients with bisphosphonate-associated osteonecrosis. J. Am. Dent. Assoc. 136: 1658-1668.
47. Pozzi, S., R. Marcheselli & S. Sacchi 2005. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. (abstract). Blood 106: 5057.
48. Tossi, P., E. Zamagni & D. Cangini 2005. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid. (abstract). Blood 106: 3461.
49. Woo, S., J. Hellstein & J. Kalmar 2006. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144: 753-776.
50. Hoff, A., B. Toth & K. Altundag 2006. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J. Clin. Oncol. 24: 8528.
51. Ruggiero, S. et al 2009. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J. Oral Maxillofac. Surg. 67: 2-12.
52. Wilkinson, G. et al 2007. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaws: A population-based analysis. J. Natl. Cancer Inst. 99: 1016-1024.
53. Mavrokokki, T. et al 2007. The nature and incidence of bisphosphonate associated osteonecrosis of the jaws in Australia. J. Oral Maxillofac. Surg. 3: 415-423.
54. Black, D., A. Schwartz & K. Ensrud 2006. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. J. Am. Med. Assoc. 296: 2927-2938.
55. Odvina, C., J. Zerwekh & R. Sudhaker 2005. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90: 1294-1301.
56. Colon-Emeric, C. 2006. Ten vs Five years of bisphosphonate treatment for postmenopausal osteoporosis. Enough of a good thing (editorial). J. Amer. Med. Assoc. 296: 2968-2969.
57. Ott, S. 2005. Long-term safety of bisphosphonates (editorial). J. Clin. Endocrinol. Metab. 90: 1897-1899.
58. Lacy, M., A. Dispenzieri & M. Gertz 2006. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin. Proc. 81: 1047-1053.
59. Mehrotra, B., J. Fantasia & S. Ruggiero 2008. Outcomes of bisphosphonate related osteonecrosis of the jaw. Importance of staging and management guidelines. A large single institutional update. J. Clin. Oncol. 26: 322-326.
60. Khosla, S. et al 2007. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society of Bone and Mineral Research. J. Bone Miner. Res. 22: 1479-1491.
61. Badros, A. et al 2007. Long-term follow-up of multiple myeloma patients with osteonecrosis of the jaw. Blood 110: 1030A-1031A.
62. Kunchur, R. et al 2009. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate -associated osteonecrosis of the jaws J. Oral Maxillofac. Surg. 67: 1167-1173.
63. Bagan, J. et al 2008. Collagen telopeptide (serum CTX) and its relationship with size and number of lesions in osteonecrosos of the jaws in cancer patients on intraveneous bisphosphonates. Oral Oncol 44: 1028-1089.
64. Kwon, Y. et al 2009. Correlation between serum C-terminal cross-linking telopeptide of type 1 collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 67: 2644-2648.
65. Lehrer, S. et al 2008. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Path oral Radiol. Endod. 106: 389-391.
66. Marx, R., J. Cillo & J. Ulloa 2007. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65: 2397-2410.
67. Rosen, H. et al 2000. Serum CTX: Anew marker of bone resorption that shows treatment effect more often than markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif. Tissue Int. 66: 100-103.
68. Rosen, H. et al 1998. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif. Tissue Int. 63: 363-368.
69. Bone, H. et al 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350: 1189-1199.